organization:johns hopkins university school of medicine

How Silicon Valley Plans to Conquer the Classroom - The New York Times
▻https://www.nytimes.com/2017/11/03/technology/silicon-valley-baltimore-schools.html?emc=edit_th_20171104&nl=todaysheadlin

https://static01.nyt.com/images/2017/11/04/business/04BIGED2/00BIGED2-facebookJumbo.jpg

Silicon Valley is going all out to own America’s school computer-and-software market, projected to reach $21 billion in sales by 2020. An industry has grown up around courting public-school decision makers, and tech companies are using a sophisticated playbook to reach them, The New York Times has found in a review of thousands of pages of Baltimore County school documents and in interviews with dozens of school officials, researchers, teachers, tech executives and parents.

Au moins en France, ils n’ont pas ce problème : c’est directement le Ministère de l’Education nationale qui a invité ses cadres aux formations et conseils délivrés par Microsoft...

School leaders have become so central to sales that a few private firms will now, for fees that can climb into the tens of thousands of dollars, arrange meetings for vendors with school officials, on some occasions paying superintendents as consultants. Tech-backed organizations have also flown superintendents to conferences at resorts. And school leaders have evangelized company products to other districts.

These marketing approaches are legal. But there is little rigorous evidence so far to indicate that using computers in class improves educational results. Even so, schools nationwide are convinced enough to have adopted them in hopes of preparing students for the new economy.

Intéressant cette notion de « pharmacy-like » technique de marketing. Il n’y a plus seulement l’industrie du tabac comme modèle de la capacité à créer un foule d’accros.

In some significant ways, the industry’s efforts to push laptops and apps in schools resemble influence techniques pioneered by drug makers. The pharmaceutical industry has long cultivated physicians as experts and financed organizations, like patient advocacy groups, to promote its products.

Studies have found that strategies like these work, and even a free $20 meal from a drug maker can influence a doctor’s prescribing practices. That is one reason the government today maintains a database of drug maker payments, including meals, to many physicians.

Tech companies have not gone as far as drug companies, which have regularly paid doctors to give speeches. But industry practices, like flying school officials to speak at events and taking school leaders to steak and sushi restaurants, merit examination, some experts say.

Several parents said they were troubled by school officials’ getting close to the companies seeking their business. Dr. Cynthia M. Boyd, a practicing geriatrician and professor at Johns Hopkins University School of Medicine with children in district schools, said it reminded her of drug makers’ promoting their medicines in hospitals.

“You don’t have to be paid by Big Pharma, or Big Ed Tech, to be influenced,” Dr. Boyd said. She has raised concerns about the tech initiative at school board meetings.

In Baltimore County and beyond, the digital makeover of America’s schools has spawned a circuit of conferences, funded by Microsoft, Google, Dell and other tech vendors, that lavish attention on tech-friendly educators.

Another way tech companies reach superintendents is to pay private businesses that set up conferences or small-group meetings with them. Superintendents nationwide have attended these events.

One prominent provider is the Education Research and Development Institute, or ERDI, which regularly gathers superintendents and other school leaders for conferences where they can network with companies that sell to schools.

ERDI has offered superintendents $2,000 per conference as participating consultants, according to a Louisiana Board of Ethics filing. And there are other perks.

“Because we are asking for their time and expertise, we commonly offer to pay the cost of their food, transportation and lodging during their participation,” ERDI’s president, David M. Sundstrom, said in an email.

#Education #Edutech #Conflits_intérêt #Pharma_marketing_model

Hallucinogen Therapy Is Coming - Issue 40: Learning
▻http://nautil.us/issue/40/learning/hallucinogen-therapy-is-coming

http://static.nautil.us/10358_44e55ed981c434536b85d307e6215b26.png

Three years later Daniel Kreitman still chokes up when he talks about what he saw, and how it changed him. Kreitman, an upholsterer by trade, had taken psilocybin, a hallucinogen derived from mushrooms, in a trial at Johns Hopkins University School of Medicine for nicotine addiction. He was 52, and he’d smoked between one and two packs a day for nearly 40 years. After his first psilocybin session, his urge to smoke was gone. During his third and final session, he had the vision that helped him quit for good.He saw lakes, roads, and mountains, and a broad-shouldered man at the helm of a ship, lassoing birds. Was it his dead father? He wasn’t sure. But he remembers giggling and feeling good. Music was playing in his headphones. During Aaron Copland’s Appalachian Spring he had the sensation (...)

‘A’-grade hospitals have 50% fewer avoidable deaths | Managed Healthcare Executive
▻http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/grade-hospitals-have-50-fewer-avoidable-deaths

http://www.hospitalsafetyscore.org/media/image/HSS_2016_LivesLost.jpg

It is much safer to receive care at an “A” hospital versus a “B,” “C,” “D” or “F” hospital, according to new analysis led by Matt Austin, PhD, assistant professor at the Armstrong Institute for Patient Safety and Quality and the Department of Anesthesiology and Critical Care Medicine at Johns Hopkins University School of Medicine. 

Leapfrog contracted with Johns Hopkins Medicine’s Armstrong Institute for Patient Safety and Quality on a new analysis estimating the number of avoidable deaths at hospitals in each grade level. The analysis finds that despite considerable improvement in the safety of hospital care since the Score’s launch in 2012, avoidable deaths remain high. 

Findings point to a 9% higher risk of avoidable death in B hospitals, 35% higher in C hospitals, and 50% higher in D and F hospitals, than in A hospitals.

The Hospital Safety Score estimates patients’ relative risk of avoidable death from errors, accidents, and infections and grades hospitals with an “A,” “B,” “C,” “D,” or “F.” The Hospital Safety Score is the only rating that focuses primarily on errors, accidents, and infections in hospitals. 

Of the 2,571 hospitals issued a Hospital Safety Score, 798 earned an “A,” 639 earned a “B,” 957 earned a “C,” 162 earned a “D” and 15 earned an “F.”

(l’image provient de l’étude citée en lien
▻http://www.hospitalsafetyscore.org/liveslost )

Campaigners vow to take clinical trial openness into their own hands : Nature News Blog
▻http://blogs.nature.com/news/2013/06/campaigners-vow-to-take-clinical-trial-openness-into-their-own-hands.h

Campaigners for more openness in clinical trial data have doubled down on their opponents, with a promise to produce their own publications of trials they deem ‘invisible’ or ‘abandoned’.

In an article in the BMJ Peter Doshi, of Johns Hopkins University School of Medicine in Baltimore, Maryland, and his colleagues say they have amassed some 178,000 pages of drug company research documents. They say they will give pharmaceutical companies time to publish their own studies on unpublished clinical trials, or to correct trials they consider misreported

#pharma #études_non_publiées #santé #recherche #data